Inhaled Iloprost for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) During Pregnancy: A Case Report

被引:4
作者
Horng, Michelle [1 ]
Mohammad, Insaf [1 ]
Smith, Zachary R. [1 ]
Awdish, Rana L. [2 ]
Cajigas, Hector R. [2 ,3 ]
机构
[1] Henry Ford Hosp, Dept Pharm, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Dept Pulm Med, Detroit, MI 48202 USA
[3] Northwestern Univ, Dept Pulm Med, Feinberg Sch Med, Chicago, IL 60611 USA
来源
PHARMACOTHERAPY | 2016年 / 36卷 / 09期
关键词
chronic thromboembolic pulmonary hypertension; pulmonary hypertension; prostacyclin analog; iloprost; pregnancy; inhaled prostacyclin; ARTERIAL-HYPERTENSION; MANAGEMENT; SILDENAFIL; GUIDELINE; DIAGNOSIS; WOMEN;
D O I
10.1002/phar.1793
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Chronic thromboembolic pulmonary hypertension (CTEPH) is a subset of pulmonary hypertension caused by acute and recurrent pulmonary emboli. Pulmonary thromboendarterectomy is the treatment of choice, but 10-50% of patients are ineligible for this procedure. We describe the case of a 25-year-old, morbidly obese (228-kg, body mass index 83.5 kg/m(2)) pregnant woman (G(3)P(2)) who presented at 24 weeks' gestation; bilateral pulmonary angiography revealed filling defects and confirmed the diagnosis of CTEPH. The patient was evaluated and deemed to present too high of a risk for pulmonary thromboendarterectomy, so a multidisciplinary team initiated medical therapy. Sildenafil 20 mg orally 3 times/day was started at week 24 of gestation, and inhaled iloprost was added at 26 weeks and titrated to 5 mu g inhaled every 2 hrs in order to optimize hemodynamic status prior to a cesarean section delivery scheduled to be performed 6 weeks later. At 32 weeks of gestation, the patient's pulmonary arterial systolic pressure was 77 mm Hg, right atrial pressure was 15 mm Hg, and pulmonary capillary wedge pressure of 16 mm Hg, and a healthy 1741-g male infant was delivered by cesarean section. The patient was transferred back to the medical intensive care unit in stable condition and discharged home 9 days following the procedure. Pharmacotherapeutic strategies for patients with CTEPH who become pregnant are limited to phosphodiesterase type 5 inhibitors and prostacyclin analog therapies due to the teratogenicity of the other drug classes used to treat the disorder (endothelin receptor antagonists and soluble guanylate cyclase stimulators). To our knowledge, this is the first case report of inhaled iloprost use in addition to oral sildenafil to improve patient symptomatology and hemodynamics during the peripartum period of a young pregnant patient with inoperable CTEPH. This drug therapy was used safely, with no noted adverse effects to the newborn or to the patient.
引用
收藏
页码:E142 / E147
页数:6
相关论文
共 50 条
  • [41] A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag
    Verlinden, Nathan J.
    Walter, Claire
    Raina, Amresh
    Benza, Raymond L.
    JOURNAL OF PHARMACY PRACTICE, 2021, 34 (06) : 980 - 983
  • [42] Exhaled breath olfactory signature of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
    Cohen-Kaminsky, Sylvia
    Sherbo, Shay
    Wang, Zhen
    Jutant, Etienne Marie
    Montani, David
    Girerd, Barbara
    Lau, Edmund
    Becquemont, Laurent
    Broza, Yoav Y.
    Haick, Hossam
    Humbert, Marc
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [43] Inhaled iloprost for the control of pulmonary hypertension
    Krug, Sabine
    Sablotzki, Armin
    Hammerschmidt, Stefan
    Wirtz, Hubert
    Seyfarth, Hans-Juergen
    VASCULAR HEALTH AND RISK MANAGEMENT, 2009, 5 : 465 - 474
  • [44] Revisiting a Distinct Entity in Pulmonary Vascular Disease: Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
    Sharma, Munish
    Levine, Deborah Jo
    MEDICINA-LITHUANIA, 2021, 57 (04):
  • [45] Chronic thromboembolic pulmonary hypertension, pregnancy, and a pulmonary endarterectomy: a rare challenge
    Rosenzweig, Erika B.
    Biscotti, Mauer
    Cleary, Kirsten
    Smiley, Richard
    Bacchetta, Matthew D.
    PULMONARY CIRCULATION, 2016, 6 (03) : 384 - 388
  • [46] Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)
    Pentikainen, Markku
    Simonen, Piia
    Leskela, Pauliina
    Harju, Terttu
    Jaaskelainen, Pertti
    Asseburg, Christian
    Oksanen, Minna
    Soini, Erkki
    Wennerstrom, Christina
    Puhakka, Airi
    FINPAH Study Grp
    PULMONARY CIRCULATION, 2025, 15 (01)
  • [47] A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
    Jang, Ji Hoon
    Jang, Hang-Jea
    Lee, Jae Ha
    LIFE-BASEL, 2024, 14 (09):
  • [48] Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension
    Lankeit, Mareike
    Krieg, Valentin
    Hobohm, Lukas
    Koelmel, Sebastian
    Liebetrau, Christoph
    Konstantinides, Stavros
    Hamm, Christian W.
    Mayer, Eckhard
    Wiedenroth, Christoph B.
    Guth, Stefan
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (02) : 250 - 258
  • [49] Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018
    Wilkens, Heinrike
    Konstantinides, Stavros
    Lang, Irene M.
    Bunck, Alexander C.
    Gerges, Mario
    Gerhardt, Felix
    Grgic, Aleksandar
    Grohe, Christian
    Guth, Stefan
    Held, Matthias
    Hinrichs, Jan B.
    Hoeper, Marius M.
    Klepetko, Walter
    Kramm, Thorsten
    Krueger, Ulrich
    Lankeit, Mareike
    Meyer, Bernhard C.
    Olsson, Karen M.
    Schaefers, Hans-Joachim
    Schmidt, Matthias
    Seyfarth, Hans-J
    Ulrich, Silvia
    Wiedenroth, Christoph B.
    Mayer, Eckhard
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 272 : 69 - 78
  • [50] Chronic thromboembolic pulmonary hypertension and schizophrenia
    Suzuki, Hideaki
    Sugimura, Koichiro
    Tatebe, Shunsuke
    Aoki, Tatsuo
    Shimokawa, Hiroaki
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 207 : 363 - 364